Alaunos Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $26.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-04-01
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2012-12-31 was -$8.03M.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2012-09-30 was -$2.28M.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $26.00K, a 96.75% decline from fiscal 2021.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $800.00K, a 166.67% increase from fiscal 2020.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $300.00K, a 72.73% decline from fiscal 2019.
- Alaunos Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $1.10M, a 1000.00% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-12-31 | $26.00K 10-K · filed 2024-04-01 | |||||
| 2021-12-31 | $800.00K 10-K · filed 2023-03-07 | |||||
| 2020-12-31 | $300.00K 10-K · filed 2022-03-30 | |||||
| 2019-12-31 | $1.10M 10-K · filed 2021-03-01 | |||||
| 2018-12-31 | $100.00K 10-K · filed 2021-03-01 | |||||
| 2017-12-31 | $200.00K 10-K · filed 2020-03-02 | $300.00K 10-K · filed 2018-03-01 | ||||
| 2016-12-31 | $800.00K 10-K · filed 2019-03-05 | $1.50M 10-K · filed 2017-02-16 | ||||
| 2015-12-31 | $23.80M 10-K · filed 2018-03-01 | |||||
| 2014-12-31 | $2.60M 10-K · filed 2017-02-16 | |||||
| 2013-12-31 | $1.40M 10-K · filed 2016-02-24 | |||||
| 2012-12-31 | -$8.03M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$10.31M derived: sum of 2 quarters · filed 2015-02-26 | $11.00K 10-K · filed 2015-02-26 | |||
| 2012-09-30 | -$2.28M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-08 | $8.04M 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | $10.32M 10-Q/A · filed 2012-08-28 | |||||
| 2011-12-31 | $2.50M 10-K · filed 2014-03-03 | |||||
| 2010-12-31 | $880.00K 10-K · filed 2013-03-18 | |||||
| 2007-08-31 | $104.00K 10-K · filed 2014-03-03 | |||||
| 2007-08-13 | $104.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |